These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17106726)

  • 1. [A contribution to the current discussion on anti-dementia drugs in Germany].
    Jessen F; Maier W
    Nervenarzt; 2007 May; 78(5):491-2, 494, 496-7. PubMed ID: 17106726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness of galantamine in a german context].
    Happich M; Schweikert B; Mühlbacher A
    Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacotherapy of patients with dementia].
    Hirsch RD
    Internist (Berl); 2003 Dec; 44(12):1584-96. PubMed ID: 14689201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counting costs. Patients will suffer from limits on Alzheimer's drugs.
    Page S
    Nurs Stand; 2005 May 25-31; 19(37):24-5. PubMed ID: 15938410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?].
    Sobów TM; Kłoszewska I
    Psychiatr Pol; 1999; 33(5):761-7. PubMed ID: 10761441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comment on: Volz A, Monsch A.U., Zahno A., Wettstein A., Stähelin H.B., Grünig R.: What did Alzheimer disease cost Switzerland in 1998? A preliminary analysis].
    Marko P
    Praxis (Bern 1994); 2000 Jul; 89(27-28):1165-6. PubMed ID: 10959206
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
    Wimo A
    Drugs Aging; 2004; 21(5):279-95. PubMed ID: 15040756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic results: tacrine].
    Ventura M; Sternon J
    Rev Med Brux; 1997 Dec; 18(6):394-7. PubMed ID: 9481161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease.
    Ballard C; Corbett A; Sharp S
    Expert Rev Neurother; 2011 Mar; 11(3):327-9. PubMed ID: 21375436
    [No Abstract]   [Full Text] [Related]  

  • 16. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 17. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic effect of cholinesterase inhibitor therapy: implications for managed care.
    Sano M
    Manag Care Interface; 2004 Aug; 17(8):44-9. PubMed ID: 15471110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early diagnosis and therapy of Alzheimer dementia. Careful documentation prevents degeneration].
    Kohler J; Riepe MW; Jendroska K; Pilartz H; Adler G; Berger FM; Calabrese P; Frölich L; Gertz HJ; Hampel H; Haupt M; Mielke R; Paulus HJ; Zedlick D
    MMW Fortschr Med; 2002 Nov; 144(47):53-4. PubMed ID: 12532523
    [No Abstract]   [Full Text] [Related]  

  • 20. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.